SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT02544204

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Juventas Therapeutics, Inc. (from the registry)
Registry
  • NCT NCT02544204
Other papers using this trial's data
  • SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial Vascular medicine (London, England), 2019-06 DOI, PubMed 30786835
  • Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients With Peripheral Artery Disease (STOP-PAD) Trial: Six-Month Results Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, 2020-08 DOI, PubMed 32419594

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02544204. Randomized; double masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease
Acronym
STOP-PAD
Condition
Peripheral Arterial Disease
Intervention (Biological)
JVS-100
Intervention (Biological)
Placebo
Lead sponsor
Juventas Therapeutics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02544204
Content hash
8833358c9a12f885f4a2011b46d601eb0ccba1220e33881e8b1e134bdd6d5270